Ignite Creation Date:
2024-05-05 @ 10:00 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00002226
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
1999-11-02
Brief Title:
Safety and Effectiveness of Giving SU5416 to HIV-Infected Patients With AIDS-Related Kaposis Sarcoma
Sponsor:
SUGEN
Organization:
NIH AIDS Clinical Trials Information Service
Study Overview
Official Title:
A Multicenter Dose Escalating Study in Patients With Cutaneous AIDS-Related Kaposis Sarcoma
Status:
COMPLETED
Status Verified Date:
2000-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to see if it is safe and effective to give SU5416 to HIV-infected patients with AIDS-related Kaposis sarcoma KS SU5416 may prevent the growth of KS tumors
Detailed Description:
Groups of 3-6 patients are sequentially assigned to receive escalating doses of SU5416 in 33 increments Study drug is administered as a twice-weekly intravenous injection for 4 weeks In the absence of unacceptable toxicity responding patients may continue on SU5416 in 4-week treatment cycles for a maximum of 1 year or until the presence of unacceptable toxicity or tumor progression
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 5416003 | None | None | None |